ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to prime immune system against breast cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can boost the body's immune attack on HER2-negative breast cancer. About 46 adults with locally advanced disease will receive this short course, then proceed to usu…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
Promising combo aims to stall advanced breast cancer
Disease control OngoingThis study tests whether adding the drug palbociclib to standard hormone and anti-HER2 therapy can help people with a specific type of advanced breast cancer (HR+/HER2+) live longer without their cancer growing. About 518 adults with metastatic breast cancer that cannot be surgic…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New hope for advanced breast cancer: drug combo trial underway
Disease control OngoingThis study tests whether adding an experimental drug (AZD5363) to standard hormone therapy (fulvestrant) can help control advanced breast cancer in postmenopausal women. About 149 women whose cancer worsened on prior hormone therapy will receive either the combo or a placebo. The…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Velindre NHS Trust • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New hope for breast cancer: hormone combo may shrink tumors better before surgery
Disease control OngoingThis phase 3 study tests whether a combination of two hormone-blocking drugs (fulvestrant and anastrozole) works better than anastrozole alone to shrink estrogen receptor-positive breast cancer before surgery. About 1,473 postmenopausal women with stage II or III breast cancer wi…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Can a simple moisturizer beat estrogen for vaginal dryness in breast cancer?
Symptom relief OngoingThis study looks at two treatments for vaginal dryness in women with estrogen-receptor-positive breast cancer who are taking aromatase inhibitors. About 33 participants will use either a vaginal estrogen ring or a Replens moisturizer for six months. The goal is to see which optio…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Polly A. Niravath, MD • Aim: Symptom relief
Last updated May 26, 2026 03:04 UTC
-
Blood tests may spare breast cancer patients from unnecessary scans
Knowledge-focused OngoingThis study looks at whether simple blood tests can tell when a scan is needed for women with metastatic breast cancer. About 97 women on standard hormone therapy will give blood samples at regular checkups. The goal is to create a smart rule that safely skips some scans, saving t…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 26, 2026 03:19 UTC
-
Can a simple scan predict breast cancer outcomes?
Knowledge-focused OngoingThis study looks at whether a special PET scan can help doctors see how well hormone therapy is working in breast cancer that has spread to the bones. About 75 adults with estrogen receptor-positive breast cancer and bone metastases will get a PET scan before starting new hormone…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC